We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · December 05, 2022

Efficacy and Safety of Low-Dose IL-2 for Primary Sjögren Syndrome

JAMA Network Open


Additional Info

JAMA Network Open
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial
JAMA Netw Open 2022 Nov 01;5(11)e2241451, J He, J Chen, M Miao, R Zhang, G Cheng, Y Wang, R Feng, B Huang, H Luan, Y Jia, Y Jin, X Zhang, M Shao, Y Wang, X Zhang, J Li, X Zhao, H Wang, T Liu, X Xiao, X Zhang, Y Su, R Mu, H Ye, R Li, X Liu, Y Liu, C Li, H Liu, F Hu, J Guo, W Liu, WB Zhang, A Jacob, JL Ambrus, C Ding, D Yu, X Sun, Z Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading